Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3060)	12/2/1997 11:59:00 AM
From: Joe E.	Respond to of 6136

<<It is a jungle out there. I may be wrong, but it seems to me that this may work out very well for them. If you read the press release closely, there may be more behind it>> I get the loss of Thymitaq as costing about $4-$5 per share. I get the decision to go it alone as costing about another $5 - $6 per share (if the cancer drug is a blockbuster then this analysis is of course wrong). Today I get a value of roughly $47-$48 for AGPH. Buyable now. This drop should flush out many short sellers, as AGPH is definitely not a stock likely to go to zero, like many shorts.